ConductScience.org, home

Paper17868596

First tuberculosis cases in Italy resistant to all tested drugs.

Migliori GB and 4 others. Euro Surveill, 2007. Cited by 126 papers, by iCite.

Cite this record

ConductScience Library. First tuberculosis cases in Italy resistant to all tested drugs. Papers, record 17868596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17868596

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
First tuberculosis cases in Italy resistant to all tested drugs.
PubMed
Journal
Euro Surveill
PubMed
Year
2007
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
126
iCite
Relative citation ratio, by iCite
3.41
iCite
Revised in PubMed
2019-06-08
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Migliori GBG B
2De Iaco GG
3Besozzi GG
4Centis RR
5Cirillo DMD M

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Drug Resistance, MicrobialMajor topic
Treatment FailureMajor topic
TuberculosisMajor topic
Adolescent
Female
Humans
Italy

Source PubMed

Download CSV of topics

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 126 citations.

PMIDTitleJournalYearIn PapersSource
42436825Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy.J R Soc N Z2026https://conductscience.org/library/papers/42436825PubMed
36964456Anti-tubercular activity evaluation of natural compounds by targeting Mycobacterium tuberculosis resuscitation promoting factor B inhibition: An in silico study.Mol Divers2024https://conductscience.org/library/papers/36964456PubMed
35479020Discovery of quinolone derivatives as antimycobacterial agents.RSC Adv2021https://conductscience.org/library/papers/35479020PubMed
34938089Risk Factors for Poor Outcomes Among Patients with Extensively Drug-Resistant Tuberculosis (XDR-TB): A Scoping Review.Infect Drug Resist2021https://conductscience.org/library/papers/34938089PubMed
33762833Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study.Infect Drug Resist2021https://conductscience.org/library/papers/33762833PubMed
33330374Handling the Hurdles on the Way to Anti-tuberculosis Drug Development.Front Chem2020https://conductscience.org/library/papers/33330374PubMed
326761512-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry.ACS Med Chem Lett2020https://conductscience.org/library/papers/32676151PubMed
32014024A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic.BMC Med2020https://conductscience.org/library/papers/32014024PubMed
31985348ATP-binding cassette (ABC) import systems of Mycobacterium tuberculosis: target for drug and vaccine development.Emerg Microbes Infect2020https://conductscience.org/library/papers/31985348PubMed
31782209Synthesis, evaluation, molecular docking, and molecular dynamics studies of novel N-(4-[pyridin-2-yloxy]benzyl)arylamine derivatives as potential antitubercular agents.Drug Dev Res2020https://conductscience.org/library/papers/31782209PubMed
30839915Dynamic model of tuberculosis considering multi-drug resistance and their applications.Infect Dis Model2018https://conductscience.org/library/papers/30839915PubMed
30618776Genome Sequences and Comparative Analysis of Two Extended-Spectrum Extensively-Drug Resistant Mycobacterium tuberculosis Strains.Front Pharmacol2018https://conductscience.org/library/papers/30618776PubMed
30617959The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.Drugs2019https://conductscience.org/library/papers/30617959PubMed
30459198Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.mBio2018https://conductscience.org/library/papers/30459198PubMed
30081525Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold.Molecules2018https://conductscience.org/library/papers/30081525PubMed
29033842Addressing the Challenges of Tuberculosis: A Brief Historical Account.Front Pharmacol2017https://conductscience.org/library/papers/29033842PubMed
28840010Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.J Thorac Dis2017https://conductscience.org/library/papers/28840010PubMed
28178199Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Int J Mol Sci2017https://conductscience.org/library/papers/28178199PubMed
28096979Bibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015).Multidiscip Respir Med2016https://conductscience.org/library/papers/28096979PubMed
28066398Insect Vectors of Disease: Untapped Reservoirs for New Antimicrobials?Front Microbiol2016https://conductscience.org/library/papers/28066398PubMed

See all 62 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17868596

GET https://conductscience.org/api/papers/v1/17868596/cited_by?page=2